Keywords: spontaneously hypertensive rats, congenic strain, metabolic syndrome, insulin resistance hypertension, cardiac fibrosis, Nr4a1, Nr4a3, Per1, Kcna5
Introduction
Dissection of the genetic background of the most prevalent multifactorial diseases including the metabolic syndrome, and its components, such as insulin resistance, dyslipidemia, obesity and hypertension, is becoming one of the major issues in current genomic research. This is not surprising considering the ever rising prevalence, morbidity, mortality and treatment costs associated with the above mentioned diseases. For this reason, numerous methods have been developed, the main being the hypothesis driven candidate gene studies (knock-out) and the hypothesis-free genome-wide association studies (GWAS). Potential candidate genes for the multifactorial diseases have been identified on every chromosome of the most commonly used model organisms. (Perusse et. al., 2005) . Genetic background of multifactorial diseases was traditionally described as polygenic. However, as indicated by some authors, the homogeneous coverage of the genome by signals from genome-wide association studies suggest an "omnigenic" hypothesis (Boyle et al., 2017) . On the other hand, stressing that some loci may have much larger effects than others led to an oligogenic hypothesis), Šeda et al., 2005; Loos et al., 2003) . Anyway, identification of causative alleles and their respective role in the pathophysiology proves to be a real challenge. However, the combination of genetically defined model organisms in combination with high-throughput technologies can undoubtedly enable us to characterize transcriptomic changes and help us to understand the genetic background of multifactorial diseases.
Spontaneously hypertensive rat (SHR hereafter) , is probably the most commonly used rodent model for essential hypertension (Loos et al., 2003 , Pravenec et al. 2013 . We previously described an SHR derived minimal congenic counterpart SHR.PD-(D8Rat42-D8Arb23)/Cub (Rat Genome Database ID: 1641851; PD5 hereafter), (Šeda et al., 2005) . PD5 strain has been established by introgression of a small segment of chromosome 8 from the PD/Cub strain (an inbred model of metabolic syndrome without hypertension, Šedová et al., 2000) , on the genetic background of SHR by repeated backcrossing. Using the high definition marker-assisted approach the congenic segment was identified as containing 788 kbp ((chr8:51,897,776-52,685,422 according to the rat reference genome version 3.4), encompassing 7 genes: Plzf, Htr3a, Htr3b, Usp28, Zw10, Tmprss5, and Drd2. Drd2 is represented in the segment only by its promoter, first noncoding exon, and part of the first intron. Sequencing the congenic segment a deletion in the noncoding sequence (with possible enhancer function) of Plzf was revealed (Liška et al., 2014) . From the phenotypic point of view PD5 displays significantly lower blood pressure, heart weight (Křen et al., 1997), lesser tendency to myocardial fibrotization (Liška et al. 2014 ) and lower triacylglycerol and cholesterol levels (Krupková et al., 2014) , when compared to SHR.
In this study, we compared the gene expression profiles of hearts of SHR and PD5 male rats to determine to what extent does the minimal congenic segment of PD5 affect gene expression and possibly identify the significantly differentially expressed genes.
Materials and methods

Rat strains
All animal related experiments were performed in agreement with the Animal Protection Law of the Czech Republic and were approved by the ethics committees of the First Faculty of Medicine, Charles University, Prague. We used SHR/OlaIpcv (SHR hereafter; RGD ID: 631848) and its minimal congenic strain SHR.PD (D8Rat42-D8Arb23)/Cub (RGD ID: 1641851, PD5 hereafter).
Both strains were bred in-house. Rats were kept under 12 hours light-dark cycle, fed standard laboratory chow and given access to water ad libitum. At 2 months of age rats were anesthetized and decapitated. Complete organs were weighted, left ventricular myocardium was snap frozen in liquid nitrogen, and used for further analysis.
RNA isolation
Total myocardial RNA was homogenized in TRIzol reagent (Invitrogen, Carlsbad, California) . After removal of phenol by chloroform, the upper aqueous phase was applied to RNeasy columns (Qiagen) and RNA purified according to the manufacturer's instructions. RNA was quantified by spectrophotometry and its integrity was assessed using 2100 Bioanalyzer on RNA-6000 NanoLabChip (Agilent, Böblingen, Germany). Only samples showing RNA integrity numbers (RIN) above 8 were used for further analysis.
Transcriptomic analysis
Four SHR and four PD5 RNA samples obtained from left ventricle myocardium were assessed using Affymetrix GeneChip® Rat Gene 2.0 arrays (Affymetrix, Santa Clara, CA, USA). Expression console software (Affymetrix, Santa Clara, CA, USA) was used to perform quality control.
Differential gene expression between strains was determined using PARTEK Genomics Suite 6.6 (Partek, St. Louis, Missouri) software. We considered a p-value lower than 0.05 as well as fold change <-1.5 or >1.5 with subsequent false discovery rate (FDR) correction, applying BenjaminiHochberg procedure, where α = 0.05 (5% FDR) . The microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE126709.
RT PCR and qPCR
One μg total RNA was used to synthesize cDNA using Superscript II reverse transcriptase (Invitrogen, Carlsbad, California) and oligo-dT primers, according to manufacturer's recommendation. The resulting cDNAs were then used as template in quantitative real-time PCR (qPCR) reactions. Primers for qPCR reactions were designed using PrimerBLAST (Ye et al., 2012) to span at least one exon-exon junction and amplification was done in 7900HT (Applied Biosystems) in Power-up SYBRGreen master mix (Thermofisher). The primers were as follows:
TaqMan® probe Rn01496761_g1 was used (Thermofisher). Cycle threshold (Ct) values were normalized against GAPDH (Taqman® chemistry, Applied Biosystems), and relative quantification was performed using the ΔΔCt method (Livak and Schmittgen, 2001) . Fold change values were calculated as the change in mRNA expression levels relative to the control. Statistical comparison was performed using Student´s two-tailed t-test on ΔΔCt values. Their normal distribution was assessed using normal probability plots (using STATISTICA13).
Nr4a1 protein expression determined by Western blotting
N-terminal rabbit monoclonal anti-Nra4a1 antibody (anti-Nur77; ab109180) was purchased from Abcam (Cambridge, UK). Monoclonal mouse anti-α-tubulin (B-5-2-1) was from Sigma-Aldrich (St.
Louis, Missouri, USA). Membranes were incubated overnight at 4°C with antibodies at final dilution 1:5000 (Nr4a1) or 1:15000 (α-tubulin), secondary HRP-conjugated antibody was from GE Healthcare Bio-Sciences (Little Chalfont, UK), and signal was detected using ECL Prime chemiluminiscent detection kit (GE Healthcare Bio-Sciences) and Hyperfilm ECL. Developed hyperfilms were scanned and densitometry performed in ImageJ. We made 3 technical replicates and used normalized average of Nr4a1/control protein density as an estimate of expression level of Nr4a1 in each rat. Theoretical molecular weight of unmodified Nr4a1 is 64 kDa. The observed signal was consistent with the expected value.
Bioinformatics
In silico analysis was performed using Ingenuity Pathway analysis (IPA; Ingenuity Systems; www.ingenuity.com; Redwood City, CA, USA) and Database for Annotation, Visualization and Integrated Discovery (DAVID, version 6.8), .
Results
Biometrical analysis of SHR and PD5
We compared 8 rats from each strain at the age of 2 months. We observed a proportional increase in whole heart and total body weight in SHR; however, heart weight relative to 100 g of total body
weight was not significantly different in this comparison (Table 1) .
Dissection of differentially expressed genes
Four SHR heart samples and four PD5 heart samples were used for microarray experiments (see Materials and Methods). After Benjamini-Hochberg correction, 18 (about 0.008 % of 220,232)
DNA probe sets were identified as significantly differentially expressed between the SHR and PD5.
These probe sets represented 10 up-regulated (Col9a1, E9PT29_RAT, Epha7, Ephb3, Nr4a1, Nr4a3, Ptprt, Reln, Smg6 and Tiam1) and 8 down-regulated (Crlf1, Dusp2, Dvl1, Kcna5, LOC500300, Nfkbia, Pax3 and Per1) known genes or loci in PD5 compared to SHR.
Bioinformatic analysis
To obtain more in-depth understanding of the above mentioned differentially expressed genes as to their function we performed a Gene ontology (GO function) enrichment of these 18 significantly differentially expressed genes using DAVID. Gene ontology terms were divided into 3 main GO categories which were GO molecular function, GO cellular compartment and GO biological 
Confirmation of differentially expressed genes
To validate the trancriptomic data, we selected four differentially expressed genes for qPCR analysis (Per1, Kcna5, Nr3a4 and Nr3a1). All the observed results were in a good concordance with the microarray data (Fig. 1 ). We were able to confirm Nr4a1 upregulation in PD5 compared to SHR also on protein level using Western blotting (Fig. 2 ).
Pathway analysis of differentially expressed genes
In silico analysis using Ingenuity Pathway analysis (IPA; Qiagen) was performed to get a better understanding of the mutual interactions among these transcripts (Fig. 3) . This analysis uncovered a wide range of possible interactions of these genes and pathways responsible for blood pressure regulation and other components of metabolic syndrome. Particularly interesting is the interaction with eNOS signaling pathway, renin-angiotensin signaling, as well as VEGF signaling pathways.
Discussion
Decreased cardiac fibrosis in PD5 compared to SHR was attributed to decreased expression of transcription factor Plzf (promyelocytic leukemia zinc finger, now called Zbtb16 zinc finger and BTB domain containing protein 16), although the decrease was modest (Liška et al., 2014) . The role of Plzf in cardiac fibrosis was confirmed using Plzf knockout heterozygotes (Liška et al., 2017) . In current study, Plzf expression difference did not reach statistical significance. This can be attributed to the modest difference of expression level in the context of whole genome assay corrected to multiple comparisons. However, some of the differentially expressed genes in this study may be regulated by Plzf. Other source of differential expression of cardiac genes can be reactive, as a result of the hypertension development. PD5 has been shown to have lower blood pressure compared to SHR (Liška et al., 2014) , but the difference is small, and was not confirmed in Plzf knock-out heterozygotes (Liška et al., 2017) . In the cohort analyzed here, the relative heart weight in PD5 is not significantly different from controls, although the trend is in the direction previously 2018). This finding is in full accordance with our data.
As far as hypertension is concerned, it was shown that Nr4a1 by down-regulation of β-catenin signaling in vascular smooth muscle cells (Cui et al., 2016 ) inhibits angiotensin induced phenotypic switch which leads to hypertension (Vukelic et al., 2014) . Interestingly however, in our experiment we saw a significant overexpresion of Nr4a1 on transcriptomic as well as on proteomic level in strain with ameliorated blood pressure. This might reflect its function as a factor preventing development of cardiac fibrosis, however in our experiment limited to whole heart left ventricle tissue, we cannot specifically dissect smooth vascular muscle cell expression. Regarding other aspects of metabolic syndrome, some authors showed protective role of Nr4a1 in atherosclerosis development (Hu et al., 2014) . Nr4a1 is also capable of reducing hepatic cholesterol based on lipid overloading, and this may be due to the decrease in LDLR and HMG-CoA reductase (HMGCR) levels (Zhang et al., 2012) . The enriched GO-terms for Nr4a1 showed an involvement of Nr4a1 in steroid receptor signaling, regulation of type B pancreatic cell proliferation, and fat cell differentiation. These processes are important for metabolic syndrome development; however, their significance for left ventricle myocardium is unknown.
Per1 is a key component of circadian loop, displaying regulatory effects on renal epithelial sodium channel gene expression (Gumz et al., 2012; Gumz et al., 2009) . Lower levels of the Per1 mRNA were associated with attenuated sodium channel expression, increased sodium excretion, and low blood pressure (Richards J. et al., 2013) . Interestingly, Per1 knockout mice develop hypertension when given a long-lasting mineralocorticoid and a high salt diet, while wild type mice do not,
suggesting that Per1 gene expression may also be involved in sodium appetite and central control of blood pressure (Solocinski et al., 2017) . However, apart from reports showing expression of Per1 in the heart (Bonaconsa et al., 2014; Richards et al., 2014) its cardiac function has not been dissected.
Kcna5 gene encodes the Kv1.5 channel crucial for carrying the ultra-rapid potassium current (IKur) (Christophersen et al., 2013) . Since the importance of normal electrophysiological environment for myocardium, any alterations within the biophysical properties of IKur are associated with higher incidence of large-scale and multi-faceted electrical and structural remodeling (Workman et al. 2001; Gonzalez de la Fuente et al., 2012) , thus leading to atrial fibrillation (Christophersen et al. 2013; Caballero et al. 2010 ) and other potentially life threatening dysrhythmias, increasing the risk of heart failure development and sudden cardiac arrest (Tomaselli et al., 1994) . There was no indication of arrythmias during the telemetric blood pressure recording in PD5 and SHR (Liška et al., 2014, unpublished data) . Whether the channel upregulation in SHR can contribute to fibrosis and hypertrophy without causing arrythmias is unknown.
To our knowledge, no direct connection among our differentially expressed genes and the genes present within the congenic segment has been reported so far, especially Zbtb16, which is apparently the quantitative trait gene (Liška et al., 2017) . This may lead to the assumption that the observed differences in expression might be a secondary effect of the phenotype. However, the rats in our experiment were just two months old and the phenotypic differences in the heart weights between the groups were not yet expressed to the extent to which they normally are in older ratstherefore we suggest that the difference in expression could be a primary effect, although there is no evidence of Zbtb16 (Plzf) causation. Interestingly, Plzf and Nr4a1 have been shown to be part of mutual exclusive pathways responsible for T-cell maturing process (O´Hagan et al., 2015) or Per1 (Leigh et al., 2016) . The relation of Zbtb16 and metabolic syndrome was recently reviewed ).
In conclusion, using microarray approach following qPCR verification we revealed several differentially expressed genes in the heart of PD5 compared to SHR. Nr4a1, upregulated in PD5 in comparison to SHR both on RNA and protein level, may play a role in the differential cardiac phenotypes of PD5 and SHR, i.e. amelioration of cardiac fibrosis in PD5.
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